Abstract
One of the main barriers to more efficacious use of modern chemotherapeutic agents, is the collateral toxicity exhibited in normal, highly proliferative tissues, primarily the haemopoietic, gastrointestinal and Pulmonary tissues. Drug resistance of tumours to these drugs compounds this problem. This review discusses the role of O6-alkylguanine-DNA alkyltransferase (ATase) in conferring protection against O6-alkylating agents in normal tissue, focusing mainly on the haemopoietic compartment. The development of mutant forms of ATase, which are resistant to the effects of soluble analogues of O6-alkylation such as O6-benzylguanine, is examined and the gene therapy approach of combining these two strategies to confer chemoprotection to vulnerable tissues whilst sensitising malignant tissue is reviewed.
Keywords: Genetic Chemoprotection, Alkylguanine-DNA-Alkyltrans-ferases, haemopoietic compartment, collateral toxicity, cytosine arabinoside
Current Gene Therapy
Title: Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Volume: 2 Issue: 1
Author(s): D. A. Hobin and L. J. Fairbairn
Affiliation:
Keywords: Genetic Chemoprotection, Alkylguanine-DNA-Alkyltrans-ferases, haemopoietic compartment, collateral toxicity, cytosine arabinoside
Abstract: One of the main barriers to more efficacious use of modern chemotherapeutic agents, is the collateral toxicity exhibited in normal, highly proliferative tissues, primarily the haemopoietic, gastrointestinal and Pulmonary tissues. Drug resistance of tumours to these drugs compounds this problem. This review discusses the role of O6-alkylguanine-DNA alkyltransferase (ATase) in conferring protection against O6-alkylating agents in normal tissue, focusing mainly on the haemopoietic compartment. The development of mutant forms of ATase, which are resistant to the effects of soluble analogues of O6-alkylation such as O6-benzylguanine, is examined and the gene therapy approach of combining these two strategies to confer chemoprotection to vulnerable tissues whilst sensitising malignant tissue is reviewed.
Export Options
About this article
Cite this article as:
Hobin A. D. and Fairbairn J. L., Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases, Current Gene Therapy 2002; 2 (1) . https://dx.doi.org/10.2174/1566523023348255
DOI https://dx.doi.org/10.2174/1566523023348255 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development and Clinical Application of Tumor-derived Exosomes in
Patients with Cancer
Current Stem Cell Research & Therapy Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) NGR-based Strategies for Targeting Delivery of Chemotherapeutics to Tumor Vasculature
Anti-Cancer Agents in Medicinal Chemistry CIAPIN1 siRNA Inhibits Proliferation, Migration and Promotes Apoptosis of VSMCs by Regulating Bcl-2 and Bax
Current Neurovascular Research Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Immune System Modulates the Function of Adult Neural Stem Cells
Current Immunology Reviews (Discontinued) A QSAR Study on Novel Series of Carbonic Anhydrase Inhibitors hCA IX—Tumor-Associated (Hypoxia)
Medicinal Chemistry Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry Actions of Melatonin, Its Structural and Functional Analogs in the Central Nervous System and the Significance of Metabolism
Central Nervous System Agents in Medicinal Chemistry Connexin Genes as Promising Therapeutic Targets in Cancers
Current Pharmacogenomics Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry Virtual Screening of Acetylcholinesterase Inhibitors Based on Machine Learning Combined with Molecule Docking Methods
Current Bioinformatics Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Current Radiopharmaceuticals Proteasome Inhibitors in Cancer Therapy
Current Drug Targets The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology